Literature DB >> 23106583

Spiral array: a new high-throughput technology covers tissue heterogeneity.

Junya Fukuoka1, Matthias D Hofer, Takashi Hori, Tomonori Tanaka, Shin Ishizawa, Kazuhiro Nomoto, Manami Saito, Takeshi Uemura, Lucian R Chirieac.   

Abstract

CONTEXT: Tissue array is a well-established technique that connects basic research with clinical applications and allows for the validation of many pathobiologic events from gene expression dysregulation to genomic aberrations. However, conventional tissue array has several limitations such as poor representation of tissue heterogeneity, destruction of donor tissue blocks due to coring, and usage of particular specimens that have limited evaluable material (tissue from thin specimens or needle biopsies).
OBJECTIVE: To show the noninferiority and superiority of the new technique named Spiral Array-which allows for improved representation of the donor tissue while keeping the architectural details of the donor block intact-to that of the conventional tissue array. We compared the morphologic features of both methods.
DESIGN: We created both Spiral Array and conventional tissue array for 25 lung adenocarcinomas and 50 multiple tumors of various organs. The degree of coverage of tissue heterogeneity was examined by observing the range of the staining intensity differences in immunohistochemistry, using cytokeratin 7 and epidermal growth factor receptor (EGFR); the degree of morphologic preservation was tested by level of accurate prediction among 3 pathologists of the histopathologic diagnosis and organ type.
RESULTS: The Spiral Array showed better representations of the range of staining intensity for EGFR (P  =  .01). The level of accuracy for predicting organ type was significantly higher in Spiral Array than conventional tissue array (P  =  .047), whereas it was not significantly different between the 2 techniques for the histologic diagnosis.
CONCLUSION: Our data indicate that Spiral Array has benefits for covering tissue heterogeneity and preserving better morphology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23106583     DOI: 10.5858/arpa.2011-0393-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

Review 1.  Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma.

Authors:  José I López; Javier C Angulo
Journal:  Curr Urol Rep       Date:  2018-01-27       Impact factor: 3.092

2.  Ki-67 is a strong prognostic marker of non-small cell lung cancer when tissue heterogeneity is considered.

Authors:  Kazuhiro Tabata; Tomonori Tanaka; Tomayoshi Hayashi; Takashi Hori; Sayuri Nunomura; Suguru Yonezawa; Junya Fukuoka
Journal:  BMC Clin Pathol       Date:  2014-05-13

3.  Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer.

Authors:  Sayuri Nakamura; Kentaro Hayashi; Yuki Imaoka; Yuka Kitamura; Yuko Akazawa; Kazuhiro Tabata; Ruben Groen; Tomoshi Tsuchiya; Naoya Yamasaki; Takeshi Nagayasu; Junya Fukuoka
Journal:  PLoS One       Date:  2017-10-19       Impact factor: 3.240

4.  High expression level of serpin peptidase inhibitor clade E member 2 is associated with poor prognosis in lung adenocarcinoma.

Authors:  Ryota Dokuni; Tatsuya Nagano; Naoe Jimbo; Hiroki Sato; Tatsunori Kiriu; Yuichiro Yasuda; Masatsugu Yamamoto; Motoko Tachihara; Kazuyuki Kobayashi; Yoshimasa Maniwa; Yoshihiro Nishimura
Journal:  Respir Res       Date:  2020-12-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.